CDXS Stock Analysis: Buy, Sell, or Hold?
CDXS - Codexis, Inc.
$1.40
-0.08 (-5.41%)
▼
5d:
-5.41%
30d:
-41.42%
90d:
-50.35%
HOLD
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 11, 2026
7d
Get Alerted When CDXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CDXS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: CDXS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: CDXS is currently trading at $1.40, which is considered oversold relative to its 30-day fair value range of $1.92 to $2.53. From a valuation perspective, the stock is trading at a discount (Forward PE: -3.8) compared to its historical average (16.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CDXS is in a strong uptrend. The price is currently testing key support at $1.38. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.58 (+370.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CDXS is in a strong uptrend. The price is currently testing key support at $1.38. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.58 (+370.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.92 -
$2.53
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.4%)
- BULLISH: Trading 370.2% below Wall St target ($6.58)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Recommendation downgraded due to -5.4% 5-day decline
Trading Range Analysis
30-Day Trading Range
$1.92 -
$2.53
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.38
Resistance Level
$2.30
Current Trend
Strong Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.78
Wall Street Target
$6.58
(+370.2%)
Revenue Growth (YoY)
102.1%
Profit Margin
-41.0%
PE vs Historical
-3.8 vs 16.6
CHEAP
Share & Embed Analysis
Last updated: August 03, 2026 1:30 AM ET
Data refreshes hourly during market hours. Next update: 2:30 AM
Data refreshes hourly during market hours. Next update: 2:30 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CDXS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Stefan Lutz
SELL
5862 shares
2026-02-24
Alison Moore
SELL
3826 shares
2026-02-06
Georgia Erbez
SELL
3826 shares
2026-02-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$87 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 47 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 47 HOLD |
